Echocardiographic Changes and Long-Term Clinical Outcomes in Pediatric Patients With Pulmonary Arterial Hypertension Treated With Bosentan for 72 Weeks: A Post-hoc Analysis From the FUTURE 3 Study

Echocardiographic Changes and Long-Term Clinical Outcomes in Pediatric Patients With Pulmonary Arterial Hypertension Treated With Bosentan for 72 Weeks: A Post-hoc Analysis From the FUTURE 3 Study

FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion (FUTURE) 3 was a 24-week open-label, prospective, and randomized phase 3 study that assessed the pharmacokinetics of bosentan 2 mg/kg b.i.d. or t.i.d. in children with pulmonary arterial hypertension (PAH). We report findings from a post-hoc...

Full description

Bibliographic Details
Main Authors: Maurice Beghetti, Rolf M. F. Berger, Damien Bonnet, Simon Grill, Catherine Lesage, Jean-Christophe Lemarie, D. Dunbar Ivy
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Pediatrics
Subjects:
pulmonary arterial hypertension
pediatrics
echocardiography
vascular disease
long-term outcomes
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2021.681538/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2021.681538/full

Similar Items